DocWire News Editors

DocwireNews

Metabolic acidosis is a risk factor for progression of chronic kidney disease (CKD). There are few data available on the impact of race and ethnicity on the association between metabolic acidosis and CKD progression. Navdeep Tangri, MD, PhD, FRCP, and colleagues conducted an analysis to examine the relationship between metabolic acidosis and adverse renal outcomes and mortality by race and ethnicity in the United States. Results of the analysis were reported during a virtual poster session at ASN Kidney Week 2020 in a poster titled Relationship Between Metabolic Acidosis and CKD Progression Is Evident Across US Racial and Ethnic Groups.
The researchers utilized a large electronic medical record (EMR) database of &gt;100 million patients from all 50 states in the United States and with all insurance types. The de-identified EMRs covered the period 2007 to 2019 and were used to identify patients with non-dialysis-dependent CKD stages 3-5. Eligible records had ≥2 years of post-index data or death within 2 years; records were grouped by baseline metabolic acidosis (12 to &lt;22 mEq/L) versus normal serum bicarbonate (22 to &lt;30 mEq/L).
The total cohort included 136,067 patients. Of those, 1328 were Asian, 15,248 were Black, 4137 were Hispanic, 111,953 were White, and 3401 were classified as other race/ethnicity. The primary end point of interest was the composite outcome of death, kidney dialysis or transplant, or a 40% decline in estimated glomerular filtration rate (eGFR) from baseline. The impact of serum bicarbonate on the composite outcome was determined using Cox proportional hazards models within each racial/ethnic group, adjusted for age, sex, eGFR, log albumin-to-creatinine ratio, diabetes, hypertension, heart failure, and Charlson Comorbidity Index score.
Of the 136,067 patients, 34.6% (n=47,032) experienced composite outcome events within 2 years: Asian, 35%; Black, 44%; Hispanic, 48%; White, 32%; and other, 48%. Serum bicarbonate was an independent predictor of the composite outcome in all racial/ethnic groups.
Adjusted hazard ratios (HR) for the composite outcome per 1 mEq/L increase in serum bicarbonate (median, 4.2 years; maximum 11.5 years of follow-up) were: Asian, 0.942 (95% confidence interval [CI], 0.917-0.968); Black, 0.976 (95% CI, 0.969-0.983); Hispanic, 0.970 (95% CI, 0.956-0.984); and White, 0.960 (95% CI, 0.957-0.963) (P&lt;.001 for all groups).
In conclusion, the researchers said, “In a large community-dwelling US population, serum bicarbonate was independently associated with adverse kidney outcomes and deaths in Asians, Blacks, Hispanics, and Whites with CKD. Since race and ethnicity are associated with other sociodemographic factors that affect health, further exploration of the potential reasons for the observed range of HRs across these groups is warranted.”
Read more here: <a href="https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3446503">https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3446503</a>
Source: Tangri N, Mathur VS, Reaven NL, Funk SE, Wesson DE. Relationship between metabolic acidosis and CKD progression is evident across US racial and ethnic groups. Abstract of a poster presented at the American Society of Nephrology virtual Kidney Week 2020 (PO0468), October 22, 2020.
Funding for this poster was provided by Tricida, Inc.

Rob Dillard

The HER2DX Genomic Test is a Feasible Tool for HER2-positive Breast Cancer Diagnosis

ESMO Breast Cancer 2024

High Levels of HbA1c Are Associated With Poorer Prognosis in Breast Cancer Patients

Breast Cancer Patients Face a Higher Risk of Cardiovascular Disease

Latest News

Metabolic Acidosis and Progression of CKD in Racial/Ethnic Groups

ASN Kidney Week 2020

Metabolic acidosis is a risk factor for progression of chronic kidney disease (CKD). There are few data available on the impact of race and ethnicity on the association ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Diabetes

Neurology

Rheumatology

Gastroenterology

Pulmonology

Ophthalmology

Infectious Diseases

— HIV

Health and Wellness

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Fellow on Call

Healthcare Unfiltered

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Career Center

Expert Interviews

Subscribe